@article{5e872f75e51f45d09c26924b5af07f35,
title = "Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013",
abstract = "Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than 20,000 people annually in the United States. There has been a veritable revolution in this disease during the past decade, with dramatic improvements in our understanding of its pathogenesis, the development of several novel agents, and a concomitant doubling in overall survival. Because multiple myeloma is a complex and wideranging disorder, its management must be guided by disease- and patient-related factors; emerging as one of the most influential factors is risk stratification, primarily based on cytogenetic features. A risk-adapted approach provides optimal therapy to patients, ensuring intense therapy for aggressive disease and minimizing toxic effects, providing sufficient but less intense therapy for low-risk disease. This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial.",
author = "Mikhael, {Joseph R.} and David Dingli and Vivek Roy and Reeder, {Craig B.} and Buadi, {Francis K.} and Hayman, {Suzanne R.} and Angela Dispenzieri and Rafael Fonseca and Taimur Sher and Kyle, {Robert A.} and Yi Lin and Russell, {Stephen J.} and Shaji Kumar and Bergsagel, {P. Leif} and Zeldenrust, {Steven R.} and Nelson Leung and Drake, {Matthew T.} and Prashant Kapoor and Ansell, {Stephen M.} and Witzig, {Thomas E.} and Lust, {John A.} and Dalton, {Robert J.} and Gertz, {Morie A.} and Keith Stewart and Rajkumar, {S. Vincent} and Asher Chanan-Khan and Lacy, {Martha Q.}",
note = "Funding Information: Potential Competing Interests: Dr Mikhael has received research funding from Onyx and Celgene . Dr Dispenzieri has received research funding from Celgene, Millenium, and Janssen . Dr Fonseca has received honoraria from Medtronic, Otsuka, Celgene, Genzyme, BMS, Lilly, Onyx, Binding Site, Millennium, and Amgen and research funding from Cylene and Onyx . Dr Kyle has received honoraria from Binding Site . Dr Kumar has received research funding from Celgene, Millennium, Abbott, Genzyme, Cephalon, and Onyx . Dr Bergsagel has received honoraria from Onyx. Dr Gertz has received honoraria from Celgene and Millennium. Dr Stewart has received honoraria from Celgene and Millennium and research funding from Onyx and Millenium . Dr Lacy has received research funding from Celgene . ",
year = "2013",
month = apr,
doi = "10.1016/j.mayocp.2013.01.019",
language = "English (US)",
volume = "88",
pages = "360--376",
journal = "Mayo Clinic proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",
}